188 related articles for article (PubMed ID: 29660428)
1. The Kinetics of Antidrug Antibodies, Drug Levels, and Clinical Outcomes in Infliximab-Exposed Patients with Immune-Mediated Disorders.
Nencini F; Vultaggio A; Pratesi S; Cammelli D; Milla M; Fiori G; Bagnoli S; Prignano F; Romagnani S; Maggi E; Matucci A
J Allergy Clin Immunol Pract; 2018; 6(6):2065-2072.e2. PubMed ID: 29660428
[TBL] [Abstract][Full Text] [Related]
2. Circulating T cells to infliximab are detectable mainly in treated patients developing anti-drug antibodies and hypersensitivity reactions.
Vultaggio A; Petroni G; Pratesi S; Nencini F; Cammelli D; Milla M; Prignano F; Annese V; Romagnani S; Maggi E; Matucci A;
Clin Exp Immunol; 2016 Dec; 186(3):364-372. PubMed ID: 27569750
[TBL] [Abstract][Full Text] [Related]
3. Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis.
Siljehult F; Ärlestig L; Eriksson C; Rantapää-Dahlqvist S
Scand J Rheumatol; 2018 Sep; 47(5):345-350. PubMed ID: 29701536
[TBL] [Abstract][Full Text] [Related]
4. IgG4 anti-infliximab in treated patients: Clinical impact and temporal evolution.
Vultaggio A; Nencini F; Carraresi A; Pratesi S; Movérare R; Eriksson C; Venemalm L; Maggi E; Matucci A
Allergy; 2018 Nov; 73(11):2172-2181. PubMed ID: 29719053
[TBL] [Abstract][Full Text] [Related]
5. Anti-infliximab Antibodies with Neutralizing Capacity in Patients with Inflammatory Bowel Disease: Distinct Clinical Implications Revealed by a Novel Assay.
Weisshof R; Ungar B; Blatt A; Dahan A; Pressman S; Waterman M; Kopylov U; Ben-Horin S; Chowers Y
Inflamm Bowel Dis; 2016 Jul; 22(7):1655-61. PubMed ID: 27120567
[TBL] [Abstract][Full Text] [Related]
6. Infliximab desensitization in patients with inflammatory bowel diseases: a safe therapeutic alternative.
Hammoudi N; Hassid D; Bonnet J; Tran Minh ML; Baudry C; Vauthier A; Chedouba L; Houzé P; Lourenco N; Aparicio T; Gornet JM; Allez M
Scand J Gastroenterol; 2024 May; 59(5):553-560. PubMed ID: 38353236
[TBL] [Abstract][Full Text] [Related]
7. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
[TBL] [Abstract][Full Text] [Related]
8. T Cell Response to Infliximab in Exposed Patients: A Longitudinal Analysis.
Pratesi S; Nencini F; Grosso F; Dies L; Bormioli S; Cammelli D; Maggi E; Matucci A; Vultaggio A;
Front Immunol; 2018; 9():3113. PubMed ID: 30687319
[TBL] [Abstract][Full Text] [Related]
9. Validation of a sample pretreatment protocol to convert a drug-sensitive into a drug-tolerant anti-infliximab antibody immunoassay.
Van Stappen T; Brouwers E; Vermeire S; Gils A
Drug Test Anal; 2017 Feb; 9(2):243-247. PubMed ID: 26990872
[TBL] [Abstract][Full Text] [Related]
10. Agreement in assessment of infliximab and adalimumab levels in rheumatoid arthritis: interlaboratory and interassay comparison.
Valor L; Hernández-Flórez D; de la Torre I; Llinares F; Rosas J; Yagüe J; Garrido J; Naredo E
Clin Exp Rheumatol; 2015; 33(5):617-23. PubMed ID: 26316061
[TBL] [Abstract][Full Text] [Related]
11. Development of an ELISA-Based Competitive Binding Assay for the Analysis of Drug Concentration and Antidrug Antibody Levels in Patients Receiving Adalimumab or Infliximab.
Hock BD; Stamp LK; Hayman MW; Keating PE; Helms ET; Barclay ML
Ther Drug Monit; 2016 Feb; 38(1):32-41. PubMed ID: 26222874
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
Murdaca G; Spanò F; Contatore M; Guastalla A; Penza E; Magnani O; Puppo F
Expert Opin Drug Saf; 2016 Jan; 15(1):43-52. PubMed ID: 26559805
[TBL] [Abstract][Full Text] [Related]
13. The optimal management of anti-drug antibodies to infliximab and identification of anti-drug antibody values for clinical outcomes in patients with inflammatory bowel disease.
Mc Gettigan N; Afridi AS; Harkin G; Lardner C; Patchett S; Cheriyan D; Harewood G; Boland K; O'Toole A
Int J Colorectal Dis; 2021 Jun; 36(6):1231-1241. PubMed ID: 33515082
[TBL] [Abstract][Full Text] [Related]
14. Allergological in vitro and in vivo evaluation of patients with hypersensitivity reactions to infliximab.
Matucci A; Pratesi S; Petroni G; Nencini F; Virgili G; Milla M; Maggi E; Vultaggio A
Clin Exp Allergy; 2013 Jun; 43(6):659-64. PubMed ID: 23711128
[TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of detecting anti-infliximab antibodies with a drug-tolerant assay: post hoc analysis of the TAXIT trial.
Van Stappen T; Vande Casteele N; Van Assche G; Ferrante M; Vermeire S; Gils A
Gut; 2018 May; 67(5):818-826. PubMed ID: 28450388
[TBL] [Abstract][Full Text] [Related]
16. Association of female sex and positive rheumatoid factor with low serum infliximab and anti-drug antibodies, related to treatment failure in early rheumatoid arthritis: results from the SWEFOT trial population.
Hambardzumyan K; Hermanrud C; Marits P; Vivar N; Ernestam S; Wallman JK; van Vollenhoven RF; Fogdell-Hahn A; Saevarsdottir S;
Scand J Rheumatol; 2019 Sep; 48(5):362-366. PubMed ID: 31244356
[No Abstract] [Full Text] [Related]
17. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing.
Stubenrauch K; Wessels U; Birnboeck H; Ramirez F; Jahreis A; Schleypen J
Clin Ther; 2010 Aug; 32(9):1597-609. PubMed ID: 20974317
[TBL] [Abstract][Full Text] [Related]
18. Detection of anti-infliximab antibodies is impacted by antibody titer, infliximab level and IgG4 antibodies: a systematic comparison of three different assays.
Afonso J; Lopes S; Gonçalves R; Caldeira P; Lago P; Tavares de Sousa H; Ramos J; Gonçalves AR; Ministro P; Rosa I; Vieira AI; Coelho R; Tavares P; Soares J; Sousa AL; Carvalho D; Sousa P; da Silva JP; Meira T; Silva Ferreira F; Dias CC; Chowers Y; Ben-Horin S; Magro F;
Therap Adv Gastroenterol; 2016 Nov; 9(6):781-794. PubMed ID: 27803733
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic Effects of Antidrug Antibodies Occurring in Healthy Subjects After a Single Dose of Intravenous Infliximab.
Ehrenpreis ED
Drugs R D; 2017 Dec; 17(4):607-613. PubMed ID: 28879645
[TBL] [Abstract][Full Text] [Related]
20. Prevention of Antidrug Antibody Formation to Infliximab in Crohn's Patients With Prior Failure of Thiopurines.
Bar-Yoseph H; Waterman M; Almog R; Billiet T; Vermeire S; Ungar B; Yanai H; Dotan I; Ben-Horin S; Chowers Y
Clin Gastroenterol Hepatol; 2017 Jan; 15(1):69-75. PubMed ID: 27404966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
